Donate
Australian & New Zealand Childrens Haematology/Oncology Group

ANZCHOG Children’s Cancer Clinical Trials Repository

The goal of the ANZCHOG Children’s Cancer Clinical Trials Repository (ACCCTR) is to provide a complete, up-to-date list of clinical trials conducted in children’s cancer centres in Australia and New Zealand.  

This repository lists clinical trials currently open. If you would like to view trials that are preparing to open, temporarily closed or recently closed you can use the study title or keyword search filter. The information provided should be used in conjunction with advice from health care professionals. 

A large number of trials that are run at our children’s cancer centres in Australia and New Zealand are international trials. Further information regarding the clinical trials listed is available on national/ international clinical trial registries such as ANZCTRclinicaltrials.gov and EU Clinical Trials Register.

Study Title Protocol ID Disease (Sub Disease) Diagnosis Stage Location Links Status Trial Open Date Trial Close Date Sites Study Type Phase Age Eligibility ANZCTR International registry ID's
International Phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones AALL1631 Leukaemia (ALL) New diagnosis NSW / QLD / WA External
Registry ≫
Open 19/04/2018 Treatment Phase 3 1 year to 21 years at diagnosis NCT03007147
A Phase 3 Trial Investigating Blinatumomab (IND# 117467& NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down Syndrome B Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy) AALL1731 Leukaemia (ALL) New diagnosis NSW / VIC / WA / SA / NZ External
Registry ≫
Open 15/10/2019 Treatment Phase 3 1 year to 31 Years NCT03914625
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL Mixed Phenotype Acute Leukemia and Disseminated B-LLy AALL1732 Leukaemia (ALL) New Diagnosis NSW / QLD / VIC / WA / SA / NZ External
Registry ≫
Open 28/10/2019 Treatment Phase 3 1 Year to 24 Years NCT03959085
Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome AAML1531 Leukaemia New diagnosis NSW / VIC / WA / NZ External
Registry ≫
Open 03/11/2015 Treatment Phase 3 90 days to 4 years NCT02521493
Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia – Chronic Phase (CML-CP) AAML18P1 Chronic Myeloid Leukaemia On treatment VIC / WA External
Registry ≫
Open 15/07/2019 Treatment Phase 2 up to 25 years NCT03817398
A phase 2 study of reduced therapy for newly diagnosed average-risk WNT-driven medulloblastoma patients ACNS1422 Medulloblastoma New diagnosis NSW / WA / SA External
Registry ≫
Open Treatment Phase 2 3 years to 22 years at the time of enrollment NCT02724579
A Phase 1/2 Trial of Selinexor (KPT-330) and Radiation Therapy in Newly-Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma (DIPG) and High-Grade Glioma (HGG) ACNS1821 Diffuse Intrinsic Pontine Glioma Newly diagnosed QLD / NZ External
Registry ≫
Open 05/05/2022 Treatment Phase 1/2 12 Months to 21 Years NCT05099003
A Phase 2 Trial of Chemotherapy Followed by Response-Based Whole Ventricular &Amp; Spinal Canal Irradiation (WVSCI) for Patients With Localized Non-Germinomatous Central Nervous System Germ Cell Tumor ACNS2021 Brain and Spinal Tumours Newly diagnosed NSW / QLD / VIC / WA / NZ External
Registry ≫
Open 04/06/2021 Treatment Phase 2 3 Years to 30 Years NCT04684368
Australian Cardio-Oncology Registry ACOR All tumour types Newly diagnosed NSW / VIC / WA / SA / TAS Open 01/09/2018 Registry Not applicable up t 35 Years
A study to evaluate the safety and tolerability and pharmacokinetics of ACT001 in children with advanced brain and solid tumors ACT001-AU-002 Advanced brain tumour
Advanced solid tumour
Relapse/refractory NSW External
Registry ≫
Open 18/09/2019 Treatment Phase 1 1 Year to 21 Years ACTRN12618001934235
Patient Responses to Treatments: An Acute Leukaemia Registry; Minimal Residual Disease testing; Molecular Subtyping and Biobanking for Future Research Acute Leukaemia Registry Leukaemia NSW / QLD / VIC / WA / TAS Open 01/04/2019 Registry Not applicable Child, Adult, Older Adult
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors AGCT1531 Germ Cell Tumour New diagnosis NSW / QLD / VIC / WA / NZ External
Registry ≫
Open 08/05/2017 Treatment Phase 3 Various depending on risk group & consult protocol NCT03067181
Multicenter Open Label Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy ALLELE (ATA129-EBV-302) EBV post transplant Refractory NSW / VIC / WA External
Registry ≫
Open 29/12/2017 Treatment Phase 3 no limits NCT03394365
Key Adverse Events After Childhood Cancer ALTE03N1 Childhood Malignant Neoplasm Previously treated QLD / WA / SA External
Registry ≫
Open 24/03/2004 Observational Not applicable up to 21 Years NCT00082745
Neuropsychological and Social and Emotional and Behavioral Outcomes in Children with Cancer ALTE07C1 All Tumour Types
New diagnosis
Relapse/refractory
QLD / VIC / WA / NZ External
Registry ≫
Open 15/09/2008 Psycho-social Not applicable 3 Years to 21 Years NCT00772200
Health Effects after Anthracycline and Radiation Therapy (HEART): Dexrazoxane and Prevention of Anthracycline-related Cardiomyopathy ALTE11C2 Leukaemia
Lymphoma
Previously treated WA External
Registry ≫
Open 05/08/2013 Late Effects Not applicable no limits NCT01790152
LEAHRN (Late Effects After High-Risk Neuroblastoma) Study ALTE15N2 Recurrent Neuroblastoma Relapse/refractory WA / NZ External
Registry ≫
Open 05/06/2017 Late Effects Not applicable 5 Years to 50 Years NCT03057626
A Phase 1B/2A Study of the Safety Tolerability and Initial Efficacy of Oral AMXT 1501 Dicaprate and Intravenous Difluoromethylornithine (DFMO) in Patients with Cancer AMXT1501-102 All Cancer Types
"New diagnosis
Relapse/refractory"
NSW External
Registry ≫
Open 29/11/2022 Interventional Phase 1/2 12 years and older (12year - 17 years separate eligibility) NCT05500508 /
A Phase 2 Randomised Study of Irinotecan/Temozolomide/Dinutuximab with or without Eflornithine (DFMO) (IND# TBD) in Children with Relapsed& Refractory or Progressive Neuroblastoma ANBL1821 Solid tumours (Neuroblastoma) Relapse/refractory NSW / QLD / VIC / WA / SA / NZ External
Registry ≫
Open 28/05/2019 Treatment Phase 2 1 Year and older NCT03794349
A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma ANHL1931 Lymphoma Newly Diagnosed NSW / QLD / VIC External
Registry ≫
Open 07/06/2021 Treatment Phase 3 2 Years and older NCT04759586
Phase 3 Accelerated BEP Trial: A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours ANZUP 1302 Germ Cell Tumour New diagnosis QLD / NZ External
Registry ≫
Open 01/02/2014 Treatment Phase 3 11 Years to 45 Years NCT02582697
A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma AOST2031 Osteosarcoma Newly diagnosed VIC / NZ External
Registry ≫
Open 13/01/2023 Treatment Phase 3 up to 50 Years  NCT05235165
A Feasibility and Randomized Phase 2/3 Study of the VEFGR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma AOST2032 Osteosarcoma Newly diagnosed VIC External
Registry ≫
Open Treatment Phase 2/3 up to 40 Years NCT05691478
A randomized phase 3 trial of fludarabine/cytarabine/gemtuzumab ozogamicin with or without venetoclax in children with relapsed AML APAL2020D Acute myeloid leukemia Relapsed/refractory QLD / VIC / WA / NZ External
Registry ≫
Open 01/10/2022 Treatment Phase 3 29 Days to 21 Years NCT05183035
Pediatric Acute Leukemia (PedAL) Screening Trial – Developing New Therapies for Relapsed Leukemias APAL2020SC Leukaemia Relapsed/refractory NSW / QLD / VIC / WA / NZ External
Registry ≫
Open 30/11/2021 Observational Not applicable up to 22 Years NCT04726241
Project: EveryChild A Registry and Eligibility Screening and Biology and Outcome Study APEC14B1 All Tumour Types NSW / QLD / VIC / WA / SA / NZ External
Registry ≫
Open 26/10/2015 Registry Not applicable up to 25 years NCT02402244
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Ensartinib in Patients With Tumors Harboring ALK or ROS1 Genomic Alterations APEC1621F All tumour types Relapsed/refractory WA External
Registry ≫
Open 17/04/2018 Treatment Phase 2 12 Months to 21 Years NCT03213652
Renal Tumors Classification Biology and Banking Study AREN03B2 Renal tumours Newly diagnosed NSW / QLD / VIC / WA / NZ External
Registry ≫
Open 27/06/2007 Observational Not applicable up to 29 Years NCT00898365
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT) AREN1921 Wilms New Diagnosis
Relapse
NSW / QLD / VIC / WA / NZ External
Registry ≫
Open 18/09/2020 Treatment Phase 2 up to 30 Years NCT04322318
A Safety Pharmacokinetic and Efficacy Study of a y-Secretase Inhibitor Nirogacestat (PF-03084014) in Children and Adolescents With Progressive Surgically Unresectable Desmoid Tumors ARST1921 Desmoid-Type Fibromatosis New Diagnosis
Relapse
NZ External
Registry ≫
Open 21/09/2020 Treatment Phase 2 12 Months to 18 Years NCT04195399
A Randomized Phase 3 Trial of Vinorelbine Dactinomycin and Cyclophosphamide (VINO-AC) Plus Maintenance Chemotherapy with Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine Dactinomycin and Cyclophosphamide (VAC) plus VINO-CPO Maintenance in Patients with High Risk Rhabdomyosarcoma (HR-RMS) ARST2031 Rhabdomyosarcoma Newly diagnosed WA External
Registry ≫
Open 12/09/2023 Treatment Phase 3 up to 50 Years NCT04994132
A Prospective Phase 3 Study of Patients With Newly Diagnosed Very Low-Risk and Low-Risk Fusion Negative Rhabdomyosarcoma ARST2032 Rhabdomyosarcoma Newly diagnosed NSW / WA / NZ External
Registry ≫
Open 09/12/2022 Treatment Phase 3 up to 21 years NCT05304585
A Multi-Center Phase 3 Randomized Trial of Matched Unrelated Donor (MUD) Versus HLA-Haploidentical Related (Haplo) Myeloablative Hematopoietic Cell Transplantation for Children Adolescents and Young Adults (AYA) With Acute Leukemia or Myelodysplastic Syndrome (MDS) ASCT2031 Leukaemia
Myelodysplastic Syndrome
Newly diagnosed NSW External
Registry ≫
Open 12/12/2023 Treatment Phase 3 6 Months to 22 Years NCT05457556
Acute Lymphoblastic Leukaemia Subtype and Side-Effects from Treatment – Nationwide analysis of severe treatment-related toxicity in childhood leukaemia ASSET Leukaemia Previously treated NSW / VIC / WA / SA / NZ External
Registry ≫
Open 20/08/2015 Registry Not applicable up to 18 years
A randomised and open-label and active controlled and safety and extrapolated efficacy study in paediatric subjects requiring anticoagulation for the treatment of a venous thromboembolic event (Phase IV) Apixaban B0661037 Venous Thromboembolism New Diagnosis
Relapse/Refractory
NSW External
Registry ≫
Open 02/08/2018 Treatment Phase 4 3 Months to 17 Years NCT02464969
A Phase 1/2 Single-arm Study to Evaluate the Safety Pharmacokinetics and Antitumor Activity of Avapritinib in Pediatric Patients with Solid Tumors Dependent on KIT or PDGFRA Signaling BLU-285-3101 Solid tumours Relapse/refractory
NSW / VIC External
Registry ≫
Open 14/10/2022 Treatment Phase 1/2 2 Years to 17 Years NCT04773782
Analysis of Total Busulfan Exposure for Once Daily Intravenous Dosing in Paediatric Haematopoietic Stem Cell Transplantation- An ANZCHOG Pilot Study Bu4Day-PK-2016 Haematopoietic Stem Cell Transplant Newly diagnosed
Relapsed/refractory
NSW / QLD / WA External
Registry ≫
Open 29/05/2017 Observational Pilot up to 18 years ACTRN12617000227392
A Phase 1/2 Study of the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adult Participants with Recurrent or Refractory Classical Hodgkin Lymphoma and Non-Hodgkin Lymphoma CA224-069 Lymphoma Relapsed/Refractory NSW / QLD / WA External
Registry ≫
Open 01/11/2022 Treatment Phase 1/2 up to 30 Years NCT05255601
A Randomized Open-Label Phase 2 Study Evaluating Abemaciclib in Combination With Irinotecan and Temozolomide in Participants With Relapsed or Refractory Ewing’s Sarcoma CAMPFIRE- J1S-MC-JP04 Ewing Sarcoma Relapsed/refractory NSW / VIC External
Registry ≫
Open 10/09/2022 Treatment Phase 2 1 Year to 39 Years NCT05440786
Developing genetically modified TCells for the treatment of paediatric solid tumours CARTpaedST Solid tumours New diagnosis Open 08/04/2018 Treatment Phase 1 up to 18 years
A Two-stage Double-blind Randomized Placebo-controlled Study to Assess the Efficacy Safety and Pharmacokinetics of Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation. CBYL719P12201 Lymphatic Malformations Newly diagnosed
Relapsed/Refractory
QLD External
Registry ≫
Open 24/11/2023 Treatment Phase 1/2 2 Years and older NCT05948943 /
Long Term Follow-Up of Patients Exposed to Lentiviral-Based CAR T-Cell Therapy CCTL019A2205B Previously treated VIC External
Registry ≫
Open 02/11/2015 Observational Not applicable Child, Adult, Older Adult NCT02445222
Phase 1b/2 Study of Carfilzomib in Combination with Dexamethasone and Mitoxantrone and PEG-asparaginase& and Vincristine (UK R3 Induction Backbone) in Children with Relapsed or Refractory Acute Lymphoblastic Leukaemia CFZ2008 / 20140106 Acute Lymphoblastic Leukaemia (ALL) Relapse/refractory NSW / QLD / VIC / WA External
Registry ≫
Open 10/09/2015 Treatment Phase 1/2 1 Month to 21 Years NCT02303821
Phase I/II multicenter study to assess efficacy and safety of ribociclib (LEE011) in combination with topotecan and temozolomide (TOTEM) in pediatric patients with relapsed or refractory neuroblastoma and other solid tumors CLEE011Q12101 Neuroblastoma
Relapse/refractory
NSW External
Registry ≫
Open 27/12/2022 Interventional Phase 1/2 12 months to 21 years NCT05429502 /
A phase i/ii open-label single-arm two-part trial to evaluate safety tolerability pharmacokinetics and anti-tumor activity of glofitamab in combination with chemoimmunotherapy in pediatric and young adult participants with relapsed/refractory mature b-cell non-hodgkin lymphoma CO43810 Non-hodgkin lymphoma Relapsed/refractory QLD / WA External
Registry ≫
Open 16/11/2022 Treatment Phase 1/2 6 Months to 30 Years NCT05533775
A pilot and surgical study of larotrectinib for treatment of children with newly-diagnosed high-grade glioma with NTRK fusion CONNECT1903 Brain and Spinal Tumours (High Grade Gliomas) New diagnosis NSW / QLD / WA External
Registry ≫
Open 08/04/2021 Treatment Pilot up to 21 years NCT04655404
Phase 2 Study of Systemic IL-6 Receptor Antagonist ACTEMRA® (tocilizumab) for the treatment of Progressive/Recurrent Pediatric Adamantinomatous Craniopharyngioma CONNECT1905 Adamantinomatous Craniopharyngioma Relapsed/refractory NSW / WA External
Registry ≫
Open 19/12/2022 Treatment Phase 2 1 Year to 25 Years NCT05233397
Phase 2 Study of the MEK Inhibitor MEKTOVI® (Binimetinib) for the Treatment of Progressive/Recurrent Pediatric Adamantinomatous Craniopharyngioma CONNECT2108 Adamantinomatous Craniopharyngioma Relapsed/refractory NSW / WA External
Registry ≫
Open 08/05/2023 Treatment Phase 2 1 Year to 25 Years NCT05286788
A Phase 1 Open-label Parallel Group Study to Investigate Olaparib Safety andTolerability Efficacy and Pharmacokinetics in Paediatric Patients with Solid Tumours D0816C00025 Solid Tumours Relapsed/refractory NSW / WA External
Registry ≫
Open 01/11/2022 Treatment Phase 1 0 Years to 18 Years NCT04236414
A Phase 2 Open-Label Multicenter Study to Evaluate the Safety and Efficacy of the Oral Pan-RAF Inhibitor DAY101 in Pediatric Patients With BRAF-Altered Recurrent or Progressive Low-Grade Glioma DAY101-001 (FIREFLY) Low-grade Glioma Relapse/refractory NSW / QLD / VIC / WA / SA External
Registry ≫
Open 17/03/2021 Treatment Phase 2 6 Months to 25 Years NCT04775485
Phase I/II Trial of Deflexifol for Refractory/Recurrent Paediatric Ependymoma DEFLEXIFOL (DART) Ependymoma
Relapsed/refractory NSW / QLD / WA External
Registry ≫
Open 28/08/2023 Treatment Phase 1/2 12 Months to 21 Years ACTRN12623000104651
International Diffuse Intrinsic Pontine Glioma (DIPG)/Diffuse Midline Glioma (DMG) Registry and Repository DIPG Diffuse Intrinsic Pontine Glioma NSW / QLD / WA / NZ External
Registry ≫
Open 30/06/2012 Registry Not applicable Child, Adult, Older Adult NCT03101813
A Phase 3 Open-label Multicenter Study of the Safety Efficacy and Pharmacokinetics of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein (rFVIIIFc-VWF-XTEN; BIVV001) in Previously Treated Pediatric Patients <12 Years of Age With Severe Hemophilia A EFC16295 Hemophilia A Recurrent/ refractory QLD External
Registry ≫
Open 19/02/2021 Treatment Phase 3 up to 12 years NCT04759131
A Phase 3 Randomized International Multicenter Trial of DAY101 Monotherapy Versus Standard of Care Chemotherapy in Patients With Pediatric Low-Grade Glioma Harboring an Activating RAF Alteration Requiring First-Line Systemic Therapy Firefly-2 Low-Grade Glioma Newly diagnosed NSW / QLD / VIC / WA / SA / NZ External
Registry ≫
Open 19/05/2023 Treatment Phase 3 up to 25 Years NCT05566795
Genomics in Acute Lymphoblastic Leukaemia ANd Thrombosis GALLANT Leukaemia New diagnosis NSW / WA Open 04/08/2021 Biology Not applicable up to 25 Years
Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors Clinical and Molecular Risk-Tailored Intensive and Compressed Induction Chemotherapy Followed by Consolidation With Randomization to Either Single Cycle or to Three Tandem Cycles of Marrow-Ablative Chemotherapy With Autologous Hematopoietic Progenitor Cell Rescue HeadStart4 Medulloblastoma
PNET
Newly diagnosed NZ External
Registry ≫
Open 01/09/2015 Treatment Phase 4 up to 10 Years NCT02875314
Post mortem tumour donation for Diffuse Intrinsic Pontine Glioma – developing DIPG cell cultures to test novel therapeutic strategies HoTRODS Diffuse Pontine Glioma
Diffuse Midline Glioma
High grade glioma
New Diagnosis
Relapse
NSW / WA External
Registry ≫
Open 17/07/2012 Observational Not applicable no limits ACTRN12612001183875
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)(HR-NBL2) HR NBL2 Neuroblastoma Newly diagnosed NSW / VIC External
Registry ≫
Open 31/03/2023 Treatment Phase 3 up to 20 years NCT04221035
A Phase 1b/2 Study of Abemaciclib in Combination With Irinotecan and Temozolomide (Part A) and Abemaciclib in Combination With Temozolomide (Part B) in Pediatric and Young Adult Patients With Relapsed/Refractory Solid Tumors and Abemaciclib in Combination With Dinutuximab GM-CSF Irinotecan and Temozolomide in Pediatric and Young Adult Patients With Relapsed/Refractory Neuroblastoma (Part C) I3Y-MC-JPCS Solid Tumours Relapsed/refractory VIC / WA External
Registry ≫
Open 09/11/2020 Treatment Phase 1/2 up to 21 Years NCT04238819
A Phase I/II Open-Label Multicenter Study Evaluating the Safety Pharmacokinetics and Efficacy of Alectinib in Pediatric Patients With ALK Fusion-Positive Solid or CNS Tumors for Whom Prior Treatment Has Proven to be Ineffective or for Whom There is No Satisfactory Treatment Available iMATRIX (GO42286) Solid tumours Relapse/refractory NSW / VIC / WA External
Registry ≫
Open 26/07/2021 Treatment Phase 1/2 up to 17 Years NCT04774718
Exploratory multinational phase I/II combination study of Nivolumab and Entinostat in children and adolescents with refractory high-risk malignancies INFORM2 NivEnt CNS Tumour
Solid Tumour
Recurrent/ refractory
NSW / VIC / WA External
Registry ≫
Open 26/07/2019 Treatment Phase 1/2 6 Years to 21 Years NCT03838042
International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis LCH-IV Langerhans Cell Histiocytosis New diagnosis NSW / QLD / VIC / WA / NZ / TAS External
Registry ≫
Open 14/04/2014 Treatment Phase 3 up to 18 years NCT02205762
Liquid biopsies for molecular monitoring of paediatric solid tumours LIBIO Solid tumours NSW Open 09/04/2019 Biology Not applicable up to 25 years
A Phase I/II Study of the Oral RET inhibitor LOXO 292 in Paediatric patients with Advanced RET-Altered Solid or Primary Central Nervous System Tumours LOXO-RET-18036 Brain and Spinal Tumours Relapse/ refractory NSW / VIC External
Registry ≫
Open 01/07/2019 Treatment Phase 1/2 6 months to 21 years NCT03899792
A Phase 1/2 Study of the Oral TRK Inhibitor LOXO-101 in Pediatric Patients With Advanced Solid or Primary Central Nervous System Tumors LOXO-TRK-15003 Solid tumours New diagnosis
Relapse/ refractory
NSW External
Registry ≫
Open 11/09/2017 Treatment Phase 1/2 up to 21 years NCT02637687
A Phase 3 Open-label Multicenter Study of the Long-term Safety and Efficacy of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein (rFVIIIFc-VWF-XTEN; BIVV001) in Previously Treated Patients With Severe Hemophilia A LTS16294 Hemophilia
Previously treated QLD External
Registry ≫
Open 23/02/2022 Treatment Phase 3 Child, Adult, Older Adult NCT04644575
A Single Arm Open-Label Phase 1b Trial of Epcoritamab in Pediatric Patients With Relapsed/Refractory Aggressive Mature B-cell Neoplasms M20-429 Indolent Non-Hodgkin Lymphoma Relapsed/refractory NSW / VIC / WA External
Registry ≫
Open 29/09/2022 Treatment Phase 1/2 1 Year to 21 Year5 NCT05206357
Phase III randomized double-blind placebo-controlled trial of metformin for cognitive recovery and white matter growth in paediatric medulloblastoma patients MetMED Medulloblastoma Previously treated NSW / VIC External
Registry ≫
Open 28/09/2022 Treatment Phase 3 7 years to 17 years ACTRN12622000045718
A Phase I/II Study of Pembrolizumab (MK-3475) in Children with advanced melanoma or a PD-L1 positive advanced and relapsed or refractory solid tumor or lymphoma MK-3475-051 Solid Tumour
Lymphoma
Relapse/ refractory NSW External
Registry ≫
Open 04/04/2016 Treatment Phase 1/2 6 months to 17 years NCT02332668
Prospective Study Registry of Peripheral Neuroblastic Tumours Presenting with Spinal Canal Involvement (SCI) NB SCI Registry Neuroblastoma NSW / QLD / VIC / WA / SA / TAS External
Registry ≫
Open 01/04/2015 Registry Not applicable up to 18 Years NCT02559804
PrOspective Non-interventional Study in Patients With Locally Advanced or Metastatic TRK Fusion Cancer Treated With Larotrectinib ON TRK Solid tumours (NTRK Gene Fusion) NSW / WA External
Registry ≫
Open 03/04/2020 Observational Not applicable no limits NCT04142437
ONC201 for the Treatment of Newly Diagnosed H3 K27M-mutant Diffuse Glioma Following Completion of Radiotherapy: A Randomized Double-Blind Placebo-Controlled Multicenter Study ONC201-108 Diffuse Glioma Newly diagnosed NSW External
Registry ≫
Open Treatment Phase 3 Child, Adult, Older Adult NCT05580562
A phase II & open-labeled & multi-center & randomized controlled trial of Vinblastine +/- Bevacizumab for the treatment of chemotherapy-naive children with unresectable or progressive low grade glioma OZM-063 (LGG Avastin) Brain and Spinal Tumours(Low Grade Gliomas) New diagnosis
Relapse/ refractory
NSW / QLD / VIC / WA / SA External
Registry ≫
Open 29/05/2018 Treatment Phase 2 6 months to 18 years old NCT02840409
Phase I clinical trial of adoptive transfer of multi-virus-specific T cells into TCRaß+/CD19+-depleted haploidentical HSCT recipients P305 Haematological diseases
"New Diagnosis
Relapse/Refractory"
VIC External
Registry ≫
Open 17/06/2020 Supportive Care Phase 1 3 months to 18 years ACTRN12620000141943
Phase I clinical trial of adoptive transfer of multi-virus-specific T cells into TCRaß+/CD19+-depleted haploidentical HSCT recipients P3505 Haematological diseases New Diagnosis
Relapse/Refractory
QLD / VIC External
Registry ≫
Open 17/06/2020 Supportive Care Phase 1 3 months to 18 years ACTRN12620000141943
A Pharmacokinetic Study of Vincristine in Infants Dosed According to BSA Banded Infant Dosing Tables and Older Children Dosed by Traditional BSA Methods PEPN22P1 Hematopoietic and Lymphoid Cell Neoplasm
Malignant Solid Neoplasm
Newly diagnosed
Relapsed/Refractory
QLD External
Registry ≫
Open 22/06/2023 Treatment Pilot up to 12 Years NCT05359237
Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma PersoMed-I Medulloblastoma Newly diagnosed NSW External
Registry ≫
Open 11/11/2022 Treatment Phase 2 15 Years and older (Child, Adult, Older Adult ) NCT04402073
A combination Therapy Trial using an Adaptive Platform Design for Children and Young Adults with Diffuse Midline Gliomas (DMGs) including Diffuse Intrinsic Pontine Gliomas (DIPGS) at Initial Diagnosis Post-Radiation Therapy and at Time of Progression PNOC022 Diffuse Midline Glioma Newly diagnosed
Relapsed/Refractory
NSW / QLD / VIC / WA / SA External
Registry ≫
Open 18/08/2022 Treatment Phase 1/2 2 Years to 39 Years NCT05009992
A Pivotal Phase 1/2 Single-Arm Open-label Study to Evaluate the Safety and Efficacy of Ponatinib with Chemotherapy in Pediatric Patients with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Who Have Relapsed or Are Resistant or Intolerant to a Prior Tyrosine Kinase Inhibitor-Containing Therapy or Who Have the T315I Mutation Ponatinib-1501 /AALL1922 Leukaemia (ALL) Relapse/ refractory VIC / WA External
Registry ≫
Open 21/02/2021 Treatment Phase 1/2 1 Year to 21 Years NCT04501614
International Pleuropulmonary Blastoma Registry for PPB DICER1 and Associated Conditions PPB DICER Pleuropulmonary Blastoma NSW / WA External
Registry ≫
Open 06/12/2015 Registry Not applicable Child, Adult, Older Adult NCT03382158
Assessment of the Utility of Family-based (Trio) Whole-genome Sequencing for Cancer Predisposition Testing in Sequential Newly Diagnosed Paediatric and Adolescent Cancer Patients PREDICT All tumour types Newly diagnosed NSW External
Registry ≫
Open 08/03/2021 Observational Not applicable up to 21 years NCT04903782
PRecISion Medicine for Children with Cancer PRISM All Tumour Types New Diagnosis
Relapse/ Refractory
NSW / VIC / WA External
Registry ≫
Open 05/09/2017 Biology Biology up to 21 years NCT03336931
A phase 1 trial of HLA-DR matched third party donor-derived fungus-specific cytotoxic T-lymphocytes in patients with invasive fungal disease post-allogeneic stem cell transplantation R3ACT Fungal Invasive Fungal Disease Newly diagnosed
Relapsed/Refractory
NSW External
Registry ≫
Open 19/08/2019 Treatment Phase 1 1 Years to 80 Years ACTRN12618001540202
Phase Ib /​ Regorafenib With Conventional Chemotherapy/​Newly Diagnosed Patients/​ Multimetastatic Ewing Sarcoma REGO-EWING Multimetastatic Ewing Sarcoma Newly diagnosed QLD / WA External
Registry ≫
Open 27/03/2023 Treatment Phase 1 2 Years to 50 Years NCT05830084
A Phase II Canadian Pediatric Brain Tumour Consortium Study of Re-Irradiation as Treatment of Progressive or Recurrent Diffuse Intrinsic Pontine Glioma ReRAD Brain and Spinal Tumours Relapsed/ refractory NSW / QLD / VIC / WA / NZ External
Registry ≫
Open 15/04/2017 Treatment Phase 2 up to 17 years NCT03126266
International Randomised Controlled Trial of Chemotherapy for the Treatment of Recurrent and Primary Refractory Ewing Sarcoma RG_13-277 (rEECur) Solid tumours (Ewings sarcoma) Relapse/ refractory NSW / QLD / VIC / WA / SA / NZ External
Registry ≫
Open 03/04/2018 Treatment Phase 2/3 4 years to 50 years ACTRN12618001825246
An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma RG_17-427 (FaR-RMS) Rhabdomyosarcoma Relapsed/ refractory NSW / QLD / VIC / WA / NZ External
Registry ≫
Open 17/09/2020 Treatment Phase 1 no limits NCT04625907
Using single-cell RNA-sequencing to identify clonal enrichment in paediatric solid tumours SCRIPT Solid tumours NSW Open 20/07/2018 Biology Not applicable up to 18 years
International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia (A randomized Phase III study conducted by the AIEOP-BFM study group) Study10 Lymphoblastic leukaemia Newly diagnosed NSW External
Registry ≫
Open 15/07/2018 Treatment Phase 3 up to 17 Years NCT03643276
A TACL Phase 1/2 Study of PO Ixazomib in combination with chemotherapy for childhood relapsed or refractory ALL and Lymphoblastic Lymphoma (Takeda) T2017-002 Leukaemia (ALL) Relapsed/ refractory NSW / VIC External
Registry ≫
Open 12/02/2019 Treatment Phase 1/2 1 Year to 21 Years NCT03817320
A retrospective cohort study of response and survival in pediatric patients with relapsed and refractory acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LLy) treated with contemporary salvage therapy T2018-001 Leukaemia (ALL)
Lymphoma (LLy)
Relapsed/refractory NSW / VIC Open 01/01/2022 Observational Not applicable up to 21 years
A Phase I Study of Tagraxofusp With or Without Chemotherapy in Pediatric Patients with Relapsed or Refractory CD123 Expressing Hematologic Malignancies T2020-006 Leukaemia (ALL)
Lymphoma
Relapsed/refractory NSW / VIC External
Registry ≫
Open 11/11/2022 Treatment Phase 1 1 Year to 21 Years NCT05476770
Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial TAPISTRY All tumour types Relapsed/ refractory NSW / VIC External
Registry ≫
Open 18/01/2021 Treatment Phase 2 no limits NCT04589845
Preventing adverse events during paediatric cancer treatment: A multi-site hybrid randomised controlled trial of catheter lock solutions (The CLOCK trial) The CLOCK Trial All tumour types QLD / VIC External
Registry ≫
Open 10/07/2023 Observational Not applicable 0 Years to 18 Years ACTRN12622000499785
A phase II study of trametinib in paediatric adolescent and young adult patients with neurofibromatosis type 1 associated plexiform neurofibromas or progressive optic pathway gliomas TiNT Solid tumours (Other Solid Tumour) Relapsed/ refractory NSW / QLD / VIC / WA / SA / NZ / TAS External
Registry ≫
Open 01/03/2021 Treatment Phase 2 3 Months to 25 Years ACTRN12620001229965
Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma TOTAL 17 Leukaemia
Lymphoma
Newly diagnosed VIC External
Registry ≫
Open 01/12/2021 Treatment Phase 2/3 1 Year to 18 Years NCT03117751
A phase 1/2 open-label safety tolerability pharmacokinetics and anti-tumour activity study of repotrectinib in paediatric and young adult subjects with advanced or metastatic malignancies harbouring ALK ROS1 or NTRK1-3 alterations TPX-0005-07 Solid tumours Relapsed/ refractory NSW / QLD / WA External
Registry ≫
Open 20/03/2020 Treatment Phase 1/2 up to 25 years NCT04094610
Precision Medicine for Every Child With Cancer ZERO2 All tumour types
Newly diagnosed
Relapsed/Refractory
NSW / QLD / SA External
Registry ≫
Open 16/12/2022 Observational Not applicable 0 Years to 25 Years NCT05504772